Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784767 · ClinicalTrials.gov registry record · Phase 1
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04784767 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 29 participants.
The verdict
NCT04784767, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.
Interventions
- BIOLOGICAL 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- DRUG Sodium chloride, USP, for injection (0.9% NaCl)
- BIOLOGICAL 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04784767
The ClinicalTrials.gov registry entry for NCT04784767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) is the first listed.
NCT04784767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04784767 about?
NCT04784767 is a clinical study titled "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19". The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.
What is the current status of trial NCT04784767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-04-05. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT04784767?
The interventions under investigation include: 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) (BIOLOGICAL), Sodium chloride, USP, for injection (0.9% NaCl) (DRUG), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04784767?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.